Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Inks Deal with MultiPlan for Access to Tests, Services

NEW YORK (GenomeWeb News) – Cancer Genetics today announced an agreement with MultiPlan, allowing healthcare providers in MultiPlan's network to offer Cancer Genetics' tests and testing services to their patients.

According to MultiPlan, it has contracts with about 800,000 providers in the US, providing access to its network products to about 57 million consumers. On Monday, Genetic Technologies announced a similar agreement with the New York-based managed-care firm for its BrevaGen breast cancer test.

"This is a tremendous opportunity for us and further validates our position in cancer diagnostics," Panna Sharma, president and CEO of Cancer Genetics, said in a statement. "We expect the MultiPlan agreement to increase access to our oncology-focused services for patients and clinicians while also improving our reimbursement rate and reducing our [days sales outstanding]."

Financial and other terms of the deal were not disclosed.